The simultaneous occurrence of BRAF, TP53, and SMAD4 mutations significantly reduced the progression-free survival (p = 4.67 × 10−3) and overall survival (p = 4.98 × 10−4) of patients with colorectal cancer (Figure 5H,I). Here, SMAD4 is linked to colorectal cancer.